search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


GPBP in autoimmunity.


- candidate number8769
- NTR NumberNTR2652
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-dec-2010
- Secondary IDsNL33086.068.10 CCMO
- Public TitleGPBP in autoimmunity.
- Scientific TitleThe role of the Goodpasture antigen binding protein in autoimmunity.
- ACRONYM
- hypothesisThe Goodpasture antigen binding protein is able to modify the activation of the immune response, therefore influencing the pathology of autoimmune diseases.
- Healt Condition(s) or Problem(s) studiedAutoimmunity, Leukocytes, GPBP
- Inclusion criteriaAutoimmune patients:
1. 18 - 50 years old;
2. Diagnosed with myasthenia gravis or multiple sclerosis.

Healthy controls:
1. 18 50 years old.
- Exclusion criteriaMinors or incapacitated adults will not be included in the study. Subjects that do not want to give their informed consent will not be included.
Healthy controls that have had previous immune-related diseases (e.g chronic inflammatory reactions, autoimmune disease, immunosuppressive treatment, ) will be excluded from this study, since the inflammatory response of these patients can be disturbed.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeobservational
- planned startdate 1-feb-2011
- planned closingdate31-jan-2012
- Target number of participants100
- InterventionsN/A
- Primary outcomeThe expression of GPBP on different subsets of leukocytes will be determined with flow cytometric analyses. With these experiments, we are able to describe which specific leukocytes express GPBP. Moreover, since we will analyse both autoimmune and healthy subjects, differences between GPBP expression on particular cell subsets in changing inflammatory conditions might be discovered.
- Secondary outcomeThe cells that express GPBP (as determined with the flow cytometric analyses of aim 1) will be brought in culture to perform in vitro experiments to determine the exact function of GPBP on these cells. Various assays exist to determine immune cell function in vitro, e.g. cytotoxicity assays for NK cells and T cells, phagocytosis measurements for macrophages, Dependent on the cell types that express GPBP, suitable assays will be chosen. The experiments will be performed in GPBP depleted and GPBP enhanced conditions. So these experiments will give us insights how GPBP can modulate immune cell activation and function.
- TimepointsN/A
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. Pilar Martinez
- CONTACT for SCIENTIFIC QUERIESDr. Pilar Martinez
- Sponsor/Initiator University Maastricht (UM)
- Funding
(Source(s) of Monetary or Material Support)
Prof. Dr. M. De Baets
- PublicationsN/A
- Brief summaryThe Goodpasture antigen binding protein (GPBP) is a protein kinase that binds and phosphorylates collagen. Increased GPBP expression has been found in different autoimmune diseases. However, the cells that produce this GPBP are not known yet. Moreover, the exact function of the protein in the immune response is also not known. Our preliminary results indicate that GPBP is able to interact with proteins of the innate immune system and that it is expressed on leukocytes involved in the innate immune response. The aim of this study is to isolate leukocytes from both patients with an autoimmune disease and healthy controls in order to determine expression levels and functions of GPBP in these cells.
- Main changes (audit trail)
- RECORD14-dec-2010 - 11-jan-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl